BioLineRx Net Tangible Assets vs Long Term Debt Analysis

BLRX Stock

USD 3.87 0.11 2.76%

BioLineRx financial indicator trend analysis is way more than just evaluating BioLineRx prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioLineRx is a good investment. Please check the relationship between BioLineRx Net Tangible Assets and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Net Tangible Assets vs Long Term Debt

Net Tangible Assets vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioLineRx Net Tangible Assets account and Long Term Debt. At this time, the significance of the direction appears to have weak relationship.

The correlation between BioLineRx's Net Tangible Assets and Long Term Debt is 0.3. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of BioLineRx, assuming nothing else is changed. The correlation between historical values of BioLineRx's Net Tangible Assets and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of BioLineRx are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Tangible Assets i.e., BioLineRx's Net Tangible Assets and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Long Term Debt

Long-term debt is a debt that BioLineRx has held for over one year. Long-term debt appears on BioLineRx balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on BioLineRx balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from BioLineRx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.Selling General Administrative is likely to rise to about 19.4 M in 2025. Issuance Of Capital Stock is likely to rise to about 22.1 M in 2025

BioLineRx fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Short Long Term Debt Total	Other Liab	Other Assets	Long Term Debt
Total Assets		0.19	0.35	0.71	0.65	0.5	-0.63	0.48	-0.21	0.77	0.05	0.83	-0.09	0.46	0.73	0.44	-0.11	0.78	0.43	0.85	0.75	0.48	0.47	-0.11	-0.39	0.65
Other Current Liab	0.19		0.94	-0.39	-0.14	0.4	-0.52	0.58	-0.15	0.09	-0.21	0.11	0.19	0.55	0.12	0.62	0.68	0.42	0.81	0.2	0.11	0.55	0.41	0.0	-0.17	0.31
Total Current Liabilities	0.35	0.94		-0.29	0.08	0.47	-0.62	0.8	-0.09	0.36	0.04	0.14	0.16	0.58	0.13	0.74	0.65	0.56	0.92	0.23	0.37	0.59	0.54	0.04	-0.16	0.44
Total Stockholder Equity	0.71	-0.39	-0.29		0.53	0.03	0.0	-0.08	-0.22	0.38	-0.07	0.78	-0.44	-0.16	0.8	-0.21	-0.42	0.3	-0.26	0.73	0.35	-0.15	-0.17	-0.3	-0.17	0.12
Property Plant And Equipment Net	0.65	-0.14	0.08	0.53		0.43	-0.34	0.32	-0.3	0.63	0.52	0.47	-0.16	0.08	0.47	0.23	-0.23	0.48	0.18	0.44	0.58	0.09	0.3	-0.06	-0.32	0.29
Net Debt	0.5	0.4	0.47	0.03	0.43		-0.74	0.36	-0.67	0.51	0.09	0.24	0.4	0.6	0.32	0.56	0.05	0.69	0.55	0.31	0.52	0.6	0.78	-0.21	-0.46	0.7
Retained Earnings	-0.63	-0.52	-0.62	0.0	-0.34	-0.74		-0.52	0.1	-0.65	-0.1	-0.31	-0.48	-0.92	-0.17	-0.75	-0.04	-0.91	-0.75	-0.4	-0.67	-0.92	-0.9	-0.21	0.54	-0.87
Accounts Payable	0.48	0.58	0.8	-0.08	0.32	0.36	-0.52		0.11	0.59	0.27	0.15	0.16	0.46	0.09	0.66	0.58	0.52	0.81	0.22	0.58	0.48	0.55	0.02	0.11	0.49
Cash	-0.21	-0.15	-0.09	-0.22	-0.3	-0.67	0.1	0.11		0.01	0.14	-0.31	0.07	0.04	-0.58	0.03	0.0	-0.17	0.01	-0.32	0.02	0.06	-0.05	0.51	0.24	-0.04
Non Current Assets Total	0.77	0.09	0.36	0.38	0.63	0.51	-0.65	0.59	0.01		0.5	0.3	0.0	0.4	0.24	0.68	-0.15	0.77	0.58	0.31	1.0	0.42	0.67	0.24	-0.4	0.74
Non Currrent Assets Other	0.05	-0.21	0.04	-0.07	0.52	0.09	-0.1	0.27	0.14	0.5		-0.29	-0.21	-0.15	-0.25	0.31	-0.27	0.16	0.22	-0.34	0.48	-0.13	0.22	0.46	-0.18	0.04
Cash And Short Term Investments	0.83	0.11	0.14	0.78	0.47	0.24	-0.31	0.15	-0.31	0.3	-0.29		-0.25	0.25	0.89	0.04	-0.13	0.46	0.08	0.99	0.28	0.25	0.05	-0.32	-0.26	0.27
Net Receivables	-0.09	0.19	0.16	-0.44	-0.16	0.4	-0.48	0.16	0.07	0.0	-0.21	-0.25		0.68	-0.43	0.11	0.2	0.18	0.19	-0.14	0.01	0.66	0.63	-0.12	-0.01	0.53
Common Stock Shares Outstanding	0.46	0.55	0.58	-0.16	0.08	0.6	-0.92	0.46	0.04	0.4	-0.15	0.25	0.68		0.02	0.59	0.15	0.73	0.65	0.35	0.42	1.0	0.85	0.08	-0.36	0.83
Short Term Investments	0.73	0.12	0.13	0.8	0.47	0.32	-0.17	0.09	-0.58	0.24	-0.25	0.89	-0.43	0.02		0.02	-0.09	0.42	0.06	0.88	0.22	0.02	-0.08	-0.43	-0.25	0.11
Non Current Liabilities Total	0.44	0.62	0.74	-0.21	0.23	0.56	-0.75	0.66	0.03	0.68	0.31	0.04	0.11	0.59	0.02		0.22	0.73	0.93	0.09	0.7	0.62	0.75	0.45	-0.37	0.62
Other Current Assets	-0.11	0.68	0.65	-0.42	-0.23	0.05	-0.04	0.58	0.0	-0.15	-0.27	-0.13	0.2	0.15	-0.09	0.22		-0.05	0.45	-0.04	-0.15	0.15	0.07	-0.18	0.56	-0.02
Other Stockholder Equity	0.78	0.42	0.56	0.3	0.48	0.69	-0.91	0.52	-0.17	0.77	0.16	0.46	0.18	0.73	0.42	0.73	-0.05		0.71	0.53	0.78	0.74	0.76	0.16	-0.57	0.8
Total Liab	0.43	0.81	0.92	-0.26	0.18	0.55	-0.75	0.81	0.01	0.58	0.22	0.08	0.19	0.65	0.06	0.93	0.45	0.71		0.16	0.6	0.67	0.72	0.27	-0.28	0.6
Total Current Assets	0.85	0.2	0.23	0.73	0.44	0.31	-0.4	0.22	-0.32	0.31	-0.34	0.99	-0.14	0.35	0.88	0.09	-0.04	0.53	0.16		0.29	0.36	0.14	-0.35	-0.25	0.35
Intangible Assets	0.75	0.11	0.37	0.35	0.58	0.52	-0.67	0.58	0.02	1.0	0.48	0.28	0.01	0.42	0.22	0.7	-0.15	0.78	0.6	0.29		0.44	0.68	0.26	-0.4	0.76
Common Stock	0.48	0.55	0.59	-0.15	0.09	0.6	-0.92	0.48	0.06	0.42	-0.13	0.25	0.66	1.0	0.02	0.62	0.15	0.74	0.67	0.36	0.44		0.86	0.11	-0.36	0.83
Short Long Term Debt Total	0.47	0.41	0.54	-0.17	0.3	0.78	-0.9	0.55	-0.05	0.67	0.22	0.05	0.63	0.85	-0.08	0.75	0.07	0.76	0.72	0.14	0.68	0.86		0.14	-0.4	0.9
Other Liab	-0.11	0.0	0.04	-0.3	-0.06	-0.21	-0.21	0.02	0.51	0.24	0.46	-0.32	-0.12	0.08	-0.43	0.45	-0.18	0.16	0.27	-0.35	0.26	0.11	0.14		-0.17	0.0
Other Assets	-0.39	-0.17	-0.16	-0.17	-0.32	-0.46	0.54	0.11	0.24	-0.4	-0.18	-0.26	-0.01	-0.36	-0.25	-0.37	0.56	-0.57	-0.28	-0.25	-0.4	-0.36	-0.4	-0.17		-0.41
Long Term Debt	0.65	0.31	0.44	0.12	0.29	0.7	-0.87	0.49	-0.04	0.74	0.04	0.27	0.53	0.83	0.11	0.62	-0.02	0.8	0.6	0.35	0.76	0.83	0.9	0.0	-0.41

Click cells to compare fundamentals

BioLineRx Account Relationship Matchups

BioLineRx fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	47.3M	81.4M	76.4M	63.9M	38.9M	51.4M
Other Current Liab	1.4M	1.2M	1.7M	15.3M	4.8M	3.3M
Total Current Liabilities	10.6M	9.7M	10.7M	42.8M	15.4M	10.8M
Total Stockholder Equity	22.0M	68.1M	50.8M	13.2M	13.5M	12.8M
Property Plant And Equipment Net	2.7M	2.3M	2.5M	1.9M	1.4M	2.0M
Net Debt	(9.1M)	(8.3M)	1.7M	7.3M	4.6M	4.8M
Retained Earnings	(278.0M)	(305.0M)	(330.0M)	(390.6M)	(399.8M)	(379.8M)
Accounts Payable	5.9M	5.6M	7.0M	10.9M	5.6M	5.1M
Cash	16.8M	13.0M	10.6M	4.3M	10.4M	9.1M
Non Current Assets Total	24.4M	24.0M	24.4M	16.7M	11.8M	11.8M
Non Currrent Assets Other	56K	25.4M	21.4M	(1.0)	(1.15)	(1.09)
Cash And Short Term Investments	22.6M	57.1M	51.1M	43.0M	19.6M	37.2M
Net Receivables	141K	142K	721K	708K	3.9M	4.1M
Common Stock Shares Outstanding	16.9M	44.2M	51.6M	64.2M	79.9M	83.9M
Short Term Investments	5.8M	44.1M	40.5M	38.7M	9.1M	8.7M
Liabilities And Stockholders Equity	47.3M	81.4M	76.4M	63.9M	38.9M	51.4M
Non Current Liabilities Total	14.6M	3.6M	14.9M	19.9M	10.0M	6.3M
Other Current Assets	152K	269.0	919.0	1.5M	534K	288.6K
Other Stockholder Equity	279.2M	339.3M	339.0M	355.5M	359.1M	237.4M
Total Liab	25.3M	13.3M	25.5M	50.7M	25.4M	16.0M
Total Current Assets	22.9M	57.4M	52.0M	47.2M	27.1M	39.6M
Accumulated Other Comprehensive Income	10.9M	12.7M	14.8M	17.0M	16.1M	11.8M
Intangible Assets	21.7M	21.7M	21.9M	14.9M	10.4M	9.4M
Common Stock	9.9M	21.1M	27.1M	31.4M	38.1M	40.0M
Short Long Term Debt Total	7.7M	4.7M	12.3M	11.6M	15.0M	15.8M
Other Liab	323K	658K	10.2M	1.9M	2.1M	2.2M
Long Term Debt	5.8M	2.7M	8.6M	6.6M	9.0M	9.4M
Short Term Debt	3.3M	2.9M	2.0M	3.7M	5.0M	5.3M
Property Plant Equipment	2.2M	3.5M	2.7M	2.3M	2.6M	2.1M
Current Deferred Revenue	1.3M	1.3M	3K	13.0M	14.9M	15.6M
Property Plant And Equipment Gross	2.7M	6.8M	2.5M	7.4M	6.3M	3.4M
Inventory	151.7K	126.7K	197.1K	2.0M	3.1M	3.3M
Net Tangible Assets	19.3M	11.5M	316K	46.4M	41.7M	22.1M
Short Long Term Debt	3.1M	2.8M	1.5M	3.1M	4.5M	4.7M
Net Invested Capital	27.9M	70.8M	61.0M	23.0M	26.9M	35.5M
Net Working Capital	12.2M	47.7M	41.3M	16.3M	11.7M	21.4M
Capital Stock	9.9M	21.1M	27.1M	31.4M	38.1M	21.3M
Capital Lease Obligations	1.9M	1.9M	2.2M	1.8M	1.6M	1.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

BioLineRx Net Tangible Assets vs Long Term Debt Analysis

Net Tangible Assets vs Long Term Debt

Net Tangible Assets vs Long Term Debt Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Long Term Debt

BioLineRx fundamental ratios Correlations

BioLineRx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioLineRx fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioLineRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Intangible Assets	+ 1.0	Non Current Assets Total
Common Stock	+ 1.0	Common Stock Shares Outstanding
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Liabilities	+ 0.94	Other Current Liab
Total Liab	+ 0.93	Non Current Liabilities Total
Total Liab	+ 0.92	Total Current Liabilities

Common Stock	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Other Stockholder Equity	- 0.91	Retained Earnings
Short Long Term Debt Total	- 0.9	Retained Earnings
Long Term Debt	- 0.87	Retained Earnings
Total Liab	- 0.75	Retained Earnings